Posted in:News Celltrion Files Three IPR Petitions Against Two More Rituximab Patents By C. Nichole Gifford April 4, 2017 Comments are off On March 31, 2017, Celltrion, Inc. (“Celltrion”) filed three new petition for inter partes review (“IPR”) of two additional patents... Read more Tagged with: Biogen, Celltrion, Genentech, IPR, Legal, News, PTAB, Rituxan®, Rituximab, Teva, USPTO http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Celltrion Targets Four More Herceptin® Patents in IPR Petitions By C. Nichole Gifford March 24, 2017 Comments are off On March 21, 2017, Celltrion, Inc. (“Celltrion”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent Nos.... Read more Tagged with: Celltrion, Genentech, Herceptin®, IPR, Legal, News, PTAB, Roche, Teva, trastuzumab, USPTO http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Celltrion Files Three IPR Petitions on Rituximab Patents By C. Nichole Gifford March 17, 2017 Comments are off Celltrion, Inc. (“Celltrion”) filed three new petitions with the Patent Trial and Appeal Board (“PTAB”) on March 15, 2017 for inter... Read more Tagged with: Biogen, Celltrion, Genentech, IPR, Legal, News, PTAB, Rituxan®, Rituximab, Roche, Teva, USPTO http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Celltrion Files IPR Petition on Herceptin® Patent By C. Nichole Gifford February 22, 2017 Comments are off Celltrion, Inc. (“Celltrion”) filed a new petition with the Patent Trial and Appeal Board (“PTAB”) on February 21, 2017 for inter... Read more Tagged with: Celltrion, Genentech, Herceptin®, IPR, Legal, News, PTAB, Roche, Teva, trastuzumab, USPTO http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus